Breast Cancer
DYNASTY-Breast-02
A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator’s Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)
Trial overview
Clinical Area
Medical Oncology
Disease / Condition
Breast cancer
Study Phase
III
Trial Identifiers
GenesisCare Location(s)
Principal Investigator(s)